Structured evidence table for Butyrate Gut Microbiome Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Butyrate Gut Microbiome Meta-Analysis | Most existing reviews either describe mechanistic pathways without systematically evaluating clinical evidence quality, or report clinical findings without grounding them in the mechanistic architecture of the axis. | 3 | Jiang Changsheng (2026) | Unraveling the gut microbiota-brain axis: Mechanisms, pathophysiology, and therapeutic opportunities |
| Butyrate Gut Microbiome Meta-Analysis | As a result, there remains a substantial gap between experimental insights and their incorporation into evidence-based therapeutic strategies. | 3 | Jiang Changsheng (2026) | Unraveling the gut microbiota-brain axis: Mechanisms, pathophysiology, and therapeutic opportunities |
| Butyrate Gut Microbiome Meta-Analysis | Importantly, most evidence in human studies remains associative rather than causal, and is influenced by inter-individual variability and methodological differences, which complicate interpretation and limit reproducibility. | 3 | Jiang Changsheng (2026) | Unraveling the gut microbiota-brain axis: Mechanisms, pathophysiology, and therapeutic opportunities |
| Butyrate Gut Microbiome Meta-Analysis | Despite the rapid expansion of literature in this field, critical challenges remain. | 3 | Jiang Changsheng (2026) | Unraveling the gut microbiota-brain axis: Mechanisms, pathophysiology, and therapeutic opportunities |
| Butyrate Gut Microbiome Meta-Analysis | Beyond these classical risk factors, gut microbiota dysbiosis is an established contributor to the pathogenesis of both disorders []. | 3 | Barakat Hassan (2026) | Probiotic Modulation of Gut Microbiota: Antioxidant Mechanisms and Clinical Benefits in Obesity and Type 2 Diabetes Management |
| Butyrate Gut Microbiome Meta-Analysis | In particular, reduced microbial diversity and loss of beneficial taxa are associated with impaired intestinal barrier function, metabolic endotoxemia, chronic low-grade inflammation, and disrupted energy homeostasis, all of which favor insulin resistance and adiposity [,]. | 3 | Barakat Hassan (2026) | Probiotic Modulation of Gut Microbiota: Antioxidant Mechanisms and Clinical Benefits in Obesity and Type 2 Diabetes Management |
| Butyrate Gut Microbiome Meta-Analysis | Microbial imbalance has been consistently associated with reductions in SCFA-producing bacteria in studies of obesity and T2DM. | 3 | Barakat Hassan (2026) | Probiotic Modulation of Gut Microbiota: Antioxidant Mechanisms and Clinical Benefits in Obesity and Type 2 Diabetes Management |
| Butyrate Gut Microbiome Meta-Analysis | 1 2 3 4 Obesity and T2DM are interrelated global epidemics caused by accelerated urbanization, dietary changes, sedentary lifestyles, and major disruptions to host metabolism []. | 3 | Barakat Hassan (2026) | Probiotic Modulation of Gut Microbiota: Antioxidant Mechanisms and Clinical Benefits in Obesity and Type 2 Diabetes Management |
Source documents